ResearcherTel Aviv UniversityActive in the last 2 years

Dov Hershkovitz

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-7954-4486; OpenAlex author ID A5042641044. Sources: OpenAlex.

Their work

Papers: 4 (first author 0, last author 3)
Trials: 0
Grants: 0
Labs led: 1
Collaborators: 8

Papers, trials and grants by year

2016: 1 paper · 2017: none · 2018: 1 paper · 2019: none · 2020: none · 2021: none · 2022: none · 2023: 1 paper · 2024: none · 2025: none · 2026: 1 paper

Papers 4

Closest collaborators

The 8 strongest of 8 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

Sarah Borsekofsky · 1 shared paper, 2023 · strength 0.26
- Paper Perineural invasion detection in pancreatic ductal adenocarcinoma using artificial intelligence. DOI 10.1038/s41598-023-40833-y ↗
Guy Lahat · 1 shared paper, 2026 · strength 0.24
- Paper Lymph node-targeted Nanovaccine Reshapes the Tumor Microenvironment to Suppress PDAC Progression and Metastasis DOI 10.21203/rs.3.rs-9958073/v1 ↗
Daniella Vaskovich‐Koubi · 1 shared paper, 2026 · strength 0.24
- Paper Lymph node-targeted Nanovaccine Reshapes the Tumor Microenvironment to Suppress PDAC Progression and Metastasis DOI 10.21203/rs.3.rs-9958073/v1 ↗
Lior Orbach · 1 shared paper, 2026 · strength 0.24
- Paper Lymph node-targeted Nanovaccine Reshapes the Tumor Microenvironment to Suppress PDAC Progression and Metastasis DOI 10.21203/rs.3.rs-9958073/v1 ↗
Helena F. Florindo · 1 shared paper, 2026 · strength 0.24
- Paper Lymph node-targeted Nanovaccine Reshapes the Tumor Microenvironment to Suppress PDAC Progression and Metastasis DOI 10.21203/rs.3.rs-9958073/v1 ↗
Ronit Satchi‐Fainaro · 1 shared paper, 2026 · strength 0.24
- Paper Lymph node-targeted Nanovaccine Reshapes the Tumor Microenvironment to Suppress PDAC Progression and Metastasis DOI 10.21203/rs.3.rs-9958073/v1 ↗
Ruth Perets · 1 shared paper, 2018 · strength 0.08
- Paper Mutant KRAS Circulating Tumor DNA Is an Accurate Tool for Pancreatic Cancer Monitoring. DOI 10.1634/theoncologist.2017-0467 ↗
Sima S. Nagawkar · 1 shared paper, 2016 · strength 0.06
- Paper Intratumor Heterogeneity of KRAS Mutation Status in Pancreatic Ductal Adenocarcinoma Is Associated With Smaller Lesions. DOI 10.1097/mpa.0000000000000562 ↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.